Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
Cancer Medicine|November 27, 2025
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS TumorsDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.Cancer Medicine|June 12, 2023
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcomaDavid S Shulman, Priscilla Merriam, Edwin Choy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2021
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric NeoplasmsHimalee S Sabnis, David S Shulman, Benjamin Mizukawa, et al.Journal of the National Cancer Institute|June 26, 2024
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group reportLenka Ilcisin, Ruxu Han, Mark Krailo, et al.JCO Precision Oncology|May 14, 2026
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN StudyHolly J Roberts, Hannah Comeau, Kelly Klega, et al.Journal of Clinical Medicine|April 30, 2021
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future PerspectivesStefan K Zöllner, James F Amatruda, Sebastian Bauer, et al.Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.Pediatric Blood & Cancer|July 21, 2020
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumorKevin X Liu, Natalie B Collins, Katie A Greenzang, et al.Cancer|July 2, 2026
Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor StudyDuncan C Ramsey, David S Shulman, Grace C Zhou, et al.Translational Oncology|June 18, 2026
Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcomaHelen F Gloege, Maria Ana Isabel C De Los Santos, Advaita Chakraborty, et al.Pageof 6